The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

In 38 immunocompromised persons who received either the RSVPreF3-AS01E (RSVA-AS01E; Arexvy) or RSVpreF (Abrysvo) vaccine, preF IgG antibody titers rose a median 4.21-fold by 4 weeks -- with 61% of the ...

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...

(RTTNews) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the potential risk of Guillain-Barré Syndrome following ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...

In 38 immunocompromised persons who received either the RSVPreF3-AS01E (RSVA-AS01E; Arexvy) or RSVpreF (Abrysvo) vaccine, preF IgG antibody titers rose a median 4.21-fold by 4 weeks -- with 61% of ...